OTC "Actual Use Studies" Subject To Financial Disclosure Requirements
This article was originally published in The Tan Sheet
Executive Summary
"Actual use studies" conducted in support of Rx-to-OTC switch or direct-to-OTC new drug applications and used to show effectiveness in the OTC setting are subject to FDA's financial disclosure requirements, according to a draft guidance clarifying the agency's February 1998 final rule.